• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 5/20/24: The Future of RBQM Adoption, AI Innovating Pregnancy Care and Cancer Screening & more


The latest news for pharma industry insiders.

The Future of RBQM Adoption

In the fifth and final part of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints look ahead to the future of risk-based quality management and what adoption will look like.

AI Innovating Pregnancy Care and Cancer Screening

According to findings collected by Cedars-Sinai, artificial intelligence can reduce serious health risks associated with pregnancy and childbirth, and improve screening for some gynecological cancers.

FDA Approves Drug for Persistently Deadly Form of Lung Cancer

The treatment is for patients with small cell lung cancer, which afflicts about 35,000 people in the US a year.

Teens are Asking Schools to Provide Mental Health Information

Teens want schools to play a bigger role in their mental health, and they trust the information they get there, according to a recent survey by the National Alliance on Mental Health (NAMI). More than two-thirds of students agree schools should teach what mental health is, and where and how to seek treatment.

Donald Tracy, MA on LinkedIn:

I sat down with Tala Fakhouri at yesterday's US Pharma and Biotech Summit regarding the view of artificial intelligence from the FDA. Thank you for taking the time to speak with me!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs